Results 141 to 150 of about 17,683 (178)

Exudative non-neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2020
To describe the clinical and multimodal imaging (MMI) features of age-related macular degeneration (AMD) eyes presenting with intraretinal exudation and no evidence of neovascularization or structural alterations of native retinal vessels.This was a retrospective review of the MMI and electronic health records for 3 consecutive patients presenting with
Tommaso Bacci, Juliet O. Essilfie, Belinda C. S. Leong, K. Bailey Freund   +3 more
openaire   +3 more sources

Review of Fibrosis in Neovascular Age-Related Macular Degeneration

American Journal of Ophthalmology, 2023
To report the diagnosis and definitions, epidemiology, risk factors, and visual outcomes of fibrosis in neovascular age-related macular degeneration (nAMD).Systematic review and meta-analysis.The review was performed using the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
KAI XIONG CHEONG, CHUI MING GEMMY CHEUNG, KELVIN YI CHONG TEO   +2 more
openaire   +2 more sources

Abicipar pegol for neovascular age-related macular degeneration

Expert Opinion on Biological Therapy, 2020
The development of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized management of neovascular age-related macular degeneration (nAMD) and serves as the standard of care for treating this chronic, progressive disease.
Rehan M, Hussain, Christina Y, Weng, Charles C, Wykoff, Raya A, Gandhi, Seenu M, Hariprasad   +4 more
openaire   +2 more sources

Association of neovascular age-related macular degeneration and hyperhomocysteinemia

American Journal of Ophthalmology, 2004
To assess the relationship between plasma homocysteine levels and exudative neovascular age-related macular degeneration (AMD).Cross-sectional study.A prospective comparative cross-sectional study was conducted in outpatient ophthalmology clinics in a university-affiliated medical institution.
Ruth, Axer-Siegel, Dan, Bourla, Rita, Ehrlich, Gad, Dotan, Yoav, Benjamini, Slava, Gavendo, Dov, Weinberger, Ben-Ami, Sela   +7 more
openaire   +2 more sources

Vitreomacular Adhesion and Neovascular Age-Related Macular Degeneration

Survey of Ophthalmology, 2012
We explore the hypothesis that vitreomacular adhesion (VMA) and vitreomacular traction (VMT) play a role in the pathogenesis and clinical course of neovascular ("wet") age-related macular degeneration (AMD). Several biological theories are offered to explain this possible association, including direct tractional force, altered vitreous oxygenation ...
Simpson, Andrew R H, Petrarca, Robert, Jackson, Timothy L   +2 more
openaire   +5 more sources

Bevacizumab for Neovascular Age-related Macular Degeneration in China

Ophthalmology, 2012
To evaluate 2 different dosing regimens of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) patients in China.Multicenter, randomized, prospective, open-label clinical trial.One hundred eighty-five patients with active neovascular AMD, exclusion of a macular scar, choroidal neovascularization not ...
Xiaoxin, Li, Yonghua, Hu, Xiaodong, Sun, Junjun, Zhang, Maonian, Zhang   +4 more
openaire   +2 more sources

Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

Annals of Pharmacotherapy, 2012
Objective: To review data regarding the efficacy and safety of bevacizumab for the treatment of neovascular age-related macular degeneration (nARMD). Data Sources: Literature was searched using MEDLINE (1976-September 2011) and EMBASE (
Jamie M, Pitlick, Kayla F, Vecera, Kylie N, Barnes, John W, Reski, Alicia B, Forinash   +4 more
openaire   +2 more sources

Aflibercept for the treatment of neovascular age-related macular degeneration

Drugs of Today, 2012
Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD.
E A, Verner-Cole, S J, Davis, A K, Lauer
openaire   +2 more sources

Innovative therapies for neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2019
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.
Hasenin, Al-Khersan, Rehan M, Hussain, Thomas A, Ciulla, Pravin U, Dugel   +3 more
openaire   +2 more sources

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Immunotherapy, 2013
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the age of 50 in the western world. Intravitreally administered anti-VEGF drugs have been developed to halt neovascular growth in AMD. Randomized trials have demonstrated the excellent safety profile and significant benefit of anti-VEGF therapy ...
David, Xu, Peter K, Kaiser
openaire   +2 more sources